Retatrutide
5mg · 99%+ Purity
Description
Buy Retatrutide peptide 5mg at 99%+ purity. Triple GLP-1/GIP/glucagon receptor agonist for weight loss and appetite research.
Disclaimer: The images on this page are for illustrative purposes only. Peptodio is an educational resource and does not sell any products, nor will we ever. We do not recommend or endorse any sellers or vendors. This information is provided for research and educational purposes only.
Research & Science
Evidence-based information about this compound
Chemical Properties
CAS Number
2381089-83-2
Molecular Formula
C221H342N46O68
Molecular Weight
4731 g/mol
Also known as:
LY3437943, GLP-1/GIP/Glucagon Triagonist
Retatrutide (LY3437943) is a novel triple-receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. This "triagonist" represents the next evolution beyond dual agonists like tirzepatide, targeting an additional metabolic pathway through glucagon receptor activation.
The peptide consists of a 39-amino acid sequence with modifications that provide an extended half-life suitable for once-weekly administration. Its unique triple mechanism addresses multiple aspects of metabolic regulation simultaneously.
Early clinical trial results have shown unprecedented efficacy in weight reduction and metabolic improvement, making retatrutide one of the most exciting compounds in current metabolic research.
Retatrutide's triple mechanism provides comprehensive metabolic effects:
- GLP-1 Receptor: Reduces appetite, enhances satiety, stimulates insulin secretion, and slows gastric emptying.
- GIP Receptor: Amplifies insulin response and may improve adipose tissue metabolism.
- Glucagon Receptor: Increases energy expenditure, promotes fat oxidation, and enhances hepatic metabolism. This third mechanism distinguishes retatrutide from dual agonists.
- Synergistic Effects: The three pathways work together to reduce energy intake while increasing energy expenditure.
- Metabolic Flexibility: The combination promotes preferential utilization of fat as fuel.
Phase 2 clinical trials of retatrutide have demonstrated remarkable weight reduction:
- Unprecedented Results: Participants receiving the highest dose achieved mean weight loss of 24.2% at 48 weeks, exceeding results from any previous pharmacological intervention.
- Dose-Dependent: Weight reduction was dose-dependent and progressive throughout the study period.
- High Response Rates: At the highest dose, 100% of participants achieved ≥5% weight loss, 93% achieved ≥10%, and 83% achieved ≥15%.
- Fat Mass Reduction: Body composition analysis showed preferential loss of fat mass with relative preservation of lean tissue.
These results have generated significant interest in retatrutide's potential for metabolic research.
Sources:
Retatrutide has shown exceptional effects on liver fat reduction:
- Liver Fat Reduction: Studies showed liver fat reductions of up to 82% at higher doses.
- Normalization Rates: 86% of participants achieved normal liver fat levels (<5%) at the highest dose.
- Beyond Weight Loss: Liver fat reductions exceeded predictions based on weight loss alone, suggesting direct hepatic effects.
- Metabolic Improvements: Accompanied by improvements in liver enzymes and metabolic markers.
The glucagon receptor activation may contribute to these hepatic effects through enhanced fatty acid oxidation.
Sources:
This information is provided for educational purposes only and is based on published scientific research. This product is intended for research use only.
